Oncobesity News Posts

Fat jabs vs weight loss ops – the best way to lose weight, live longer and slash your risk of deadly diseases revealed
WEIGHT loss injections and weight loss surgery are both effective ways to slim down. But one may lead to longer life and fewer serious health

Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity
Nature Medicine, Published online: 16 September 2025; doi:10.1038/s41591-025-03893-3 In an observational study comparing individuals with type 2 diabetes and obesity who underwent metabolic surgery with

Physiologia, Vol. 5, Pages 34: The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms
Physiologia, Vol. 5, Pages 34: The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms Physiologia doi: 10.3390/physiologia5030034 Authors: Masab Mansoor

Triple Dose Of Ozempic Safe, More Effective For Weight Loss
TUESDAY, Sept. 16, 2025 — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show.Obese folks lost more weight taking 7.2 mg of semaglutide (…

Triple Dose Of Ozempic Safe, More Effective For Weight Loss
TUESDAY, Sept. 16, 2025 — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show.
Obese folks lost more weight taking 7.2 mg of…

Bariatric surgery for weight loss shows greater long-term benefits than GLP-1 medicines
A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious

What Hospitalists Should Know About GLP-1s
Delayed gastric emptying, potential aspiration risks, and medication interactions — learn the hospitalist’s approach to managing patients on GLP-1 therapy. Medscape Medical News

12 weeks to slim down for Christmas with 12 tips and not a fat jab in sight
IT’S just 12 weeks until party season, but a summer of barbecues, beers and ice cream may have left its mark on your waistline. Does

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity
A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents

Berry Street Introduces GLP-1 Nutrition Program
Berry Street’s new GLP-1 nutrition program supports patients who are starting GLP-1s, currently taking them or transitioning off of them. Patients receive care from registered

NEW STUDY: Ozempic Causes Hair Loss?! Findings + How You Can Stop This
Do GLP-1 drugs like Ozempic & Wegovy cause hair loss? A new study is sparking concern that weight loss and insulin management drugs, such as

Help, my husband’s lost his zest for life and sex drive – excessive burping keeps him awake
WE are taught to brush our teeth from a young age for a bright smile and fresh breath. And while those things are true, there

Taking semaglutide turns down food noise, research suggests
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

About one in five people taking Ozempic, Wegovy or Mounjaro say food tastes saltier or sweeter than before
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) shows that some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before.

Semaglutide, Tirzepatide Cost-Effective in Knee OA, Obesity?
Tirzepatide is more cost-effective than semaglutide for knee osteoarthritis and obesity, optimizing resources for patients not seeking surgical options, which remain cost-effective for those eligible. Medscape Medical News

Tirzepatide found to be more cost-effective than semaglutide in patients with knee osteoarthritis, obesity
A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and obesity compared with usual care, diet and exercise, and weight loss surgeries.

Treating Aging as the Cure for the Pharmaceutical Industry’s Financial Woes
The pharmaceutical industry suffers from all of the issues that plaque heavily regulated industries that have been heavily regulated for a long time. Costs increase,

Higher-Dose Semaglutide Injection Proves Mettle in Phase III Trials
(MedPage Today) — Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults with obesity, both with and without type 2 diabetes, but did not increase the risk of serious adverse events…

Fat jabs could work for children as young as SIX – but scientists issue warning over side effects
WEIGHT loss jabs could be given to children as young as six to treat obesity or type 2, researchers suggest. But stomach problems were “significantly

WHO Backs Weight-Loss Drugs for Obesity
An expert committee concluded that GLP-1 drugs are integral to developing a global standard of care for obesity, according to draft guidance from the agency.

Benefit vs. Brand: The New Economy of Functional Food Design
This industry perspective is by Justine Allan, Executive Director of Strategic Business Development at Pearlfisher. Not too long ago, taste was everything. Snacks earned loyalty,

Youth mental health challenges keep mounting 2 years after Maui wildfires
By MEGAN TAGAMI of Honolulu Civil Beat, CAROLYN JONES of CalMatters and TATIANA DÍAZ RAMOS of Centro de Periodismo Investigativo LAHAINA, Hawaii (AP) — Mia

Research finds half of Ozempic patients quit within a year
Half of people who start taking the GLP-1 weight-loss drugs Ozempic and Wegovy drop it within a year, Danish researchers reported at a conference in

Why Weight-Loss Drugs Alone Won’t Make Us Healthy
We are entering a new era of obesity. The science of weight loss has changed forever: Drugs like Ozempic, Wegovy, and Mounjaro are helping millions

FDA expands label for Krystal’s gene therapy; The latest on Novo Nordisk’s Wegovy
Plus, news about Revvity, Ocugen and Kwangdong: 🏛️ FDA expands label for Krystal Biotech’s gene therapy: Vyjuvek, which is used to treat a skin condition

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Shares of Regeneron Pharmaceuticals (REGN) have lost 21.1% year to date against the industry’s growth of 5.2%. The stock has also underperformed the sector and

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes
This systematic review and meta-analysis assesses the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity, prediabetes, or

New Molecules and Indications for GLP-1 Medicines
This Perspective explores recent progress and future directions in glucagon-like peptide-1 medicines.

New fat jab ‘golden dose’ is ‘safe and more effective’ – blasting nearly a FIFTH of body weight
A HIGHER ‘golden dose’ of Wegovy than is currently approved is safe and could be more effective – helping patients lose nearly a fifth of

GLP-1: Promising Option to Counter Antipsychotic Weight Gain
Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and prediabetes compared with placebo, new research shows. Medscape Medical

Real-World Study Finds Over 50% Stop GLP-1s Within 1 Year
More than half the adults in Denmark without diabetes have discontinued semaglutide for weight loss within a year, with young adults most likely to stop

Most quit breakthrough weight-loss drug within a year – ScienceDaily
Most quit breakthrough weight-loss drug within a year ScienceDaily Half of people on weight loss drugs quit within one year, study finds Euronews.com Top concern about Ozempic-like

Half Of Ozempic Weight-Loss Users Drop The Drug Within A Year
By Dennis Thompson HealthDay ReporterMONDAY, Sept. 15, 2025 (HealthDay News) — Half of people who start taking the GLP-1 weight-loss drug Ozempic…

Half Of Ozempic Weight-Loss Users Drop The Drug Within A Year
MONDAY, Sept. 15, 2025 — Half of people who start taking the GLP-1 weight-loss drug Ozempic drop it within a year, a new study says.About 52% of people in Denmark prescribed semaglutide (Ozempic, Wegovy) for weight loss stopped taking it after one y…

Half Of Ozempic Weight-Loss Users Drop The Drug Within A Year
MONDAY, Sept. 15, 2025 — Half of people who start taking the GLP-1 weight-loss drug Ozempic drop it within a year, a new study says.
About 52% of people in Denmark prescribed semaglutide (Ozempic, Wegovy) for weight loss stopped taking it…

Obesity
“Yes, luck would be easier to blame things on,” I nodded. “Luck is something outside of our control. It is popular, because it allows us

1 in 8 Americans Have Taken GLP-1 Weight Loss Drugs
RAND Corporation GLP-1 agonists are a class of medications that are prescribed to manage blood sugar for those with type 2 diabetes and to treat

The cancer symptoms you should NEVER dismiss as fat jab ‘side effects’ – after mum given months to live
ALL medications, including prescription drugs, over-the-counter medicines, and even herbal remedies, have the potential to cause side effects. But experts have warned weight loss jab

A week in security (September 8 – September 14)
Last week on Malwarebytes Labs: Introduction to Malware Binary Triage (IMBT) Course Looking to level up your skills? Get 10% off using coupon code: MWNEWS10

A week in security (September 8 – September 14)
Last week on Malwarebytes Labs: AI browsers or agentic browsers: a look at the future of web surfing From Fitbit to financial despair: How one